Mumbai, India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has received final approval from the US Food and Drug Administration (FDA) for its Olmesartan Medoxomil Tablets, a blood pressure treatment, the company reported on Friday.

The FDA has granted the drug approval in dose strengths of 5 mg, 20 mg and 40 mg. The drug is the generic equivalent of Benicar Tablets of Daiichi Sankyo Inc.

The Olmesartan Medoxomil tablets are set to be manufactured at the company's Goan production facility.

A statement by the company read: "Glenmark's current portfolio consists of 115 products authorised for distribution in the US marketplace and approximately 69 ANDAs pending approval with the US FDA.

"In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio."